Dopaminergic Agonists in Parkinson's Disease

Encyclopedia of Movement Disorders

Volumn , Issue , 2010, Pages 332-337

  LeWitt, P A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Dopamine receptor; Dopaminergic agonist; Parkinson's disease; Striatum

Indexed keywords

EID: 85006243865     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374105-9.00234-3     Document Type: Chapter

References (14)

1. Calne D.B., Teychenne P.F., Claveria L.E., et al. Bromocriptine in parkinsonism. British Medical Journal 1974, 4:442-444.
2. Eggert K.M., Reese J.P., Oertel W.H., Dodel R. Cost effectiveness of pharmacotherapies in early Parkinson's disease. CNS Drugs 2008, 22:841-860.
3. Ferrari-Toninelli G., Bonini S.A., Cenini G., et al. Dopamine receptor agonists for protection and repair in Parkinson's disease. Current Topics in Medicinal Chemistry 2008, 8:1089-1099.
4. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment in advanced Parkinson's disease. Neurology 1997, 49:1060-1065.
5. Haq I.U., LeWitt P.A., Fernandez H.H. Apomorphine therapy in Parkinson's disease: A review. Expert Opinion in Pharmacotherapy 2007, 8:2799-2809.
6. LeWitt P.A. Pharmacology of dopaminergic agonists for Parkinson's disease. Parkinson's Disease: The Treatment Options 1999, 159-196. Martin Dunitz Publishers, London. P.A. LeWitt, W.H. Oertel (Eds.).
7. LeWitt P.A., Lyons K.E., Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system (PREFER Study). Neurology 2007, 68:1262-1267. SP 650 Study Group.
8. Pramipexole vs. levodopa as initial treatment for Parkinson disease. Journal of the American Medical Association 2000, 284:1931-1938. Parkinson Study Group.
9. Rascol O., Brooks D., Korczyn A., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. New England Journal of Medicine 2000, 342:1484-1491.
10. Rascol O., Nutt J.G., Blin O., et al. Induction by a dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson's disease. Archives of Neurology 2001, 58:249-254.
11. Schwab R.S., Amador L.V., Lettvin L.Y. Apomorphine in Parkinson's disease. Transactions of the American Neurological Association 1951, 76:251-253.
12. Shannon K.M., Bennett J.P., Friedman J.H., et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997, 49:724-728.
13. Whone A.L., Remy P., Davis M.R., et al. Slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Annals of Neurology 2003, 54:93-101.
14. Yamamoto M., Schapira A.H. Dopamine agonists in Parkinson's disease. Expert Reviews in Neurotherapeutics 2008, 8:671-677.